Zoetis Inc. $ZTS Shares Sold by Ownership Capital B.V.

Ownership Capital B.V. reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 24.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 543,579 shares of the company’s stock after selling 172,567 shares during the period. Zoetis comprises about 4.9% of Ownership Capital B.V.’s investment portfolio, making the stock its 10th biggest position. Ownership Capital B.V.’s holdings in Zoetis were worth $84,771,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. acquired a new stake in Zoetis in the 1st quarter valued at about $25,000. 1248 Management LLC acquired a new stake in Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank acquired a new stake in Zoetis in the 1st quarter valued at about $29,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after acquiring an additional 88 shares in the last quarter. Finally, REAP Financial Group LLC increased its position in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 1.3%

Shares of NYSE ZTS opened at $145.62 on Wednesday. The stock has a market cap of $64.53 billion, a P/E ratio of 25.06, a P/E/G ratio of 2.37 and a beta of 0.90. The firm has a 50 day moving average price of $147.88 and a 200 day moving average price of $153.51. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a 52-week low of $139.34 and a 52-week high of $184.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the firm posted $1.56 earnings per share. The business’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.4%. Zoetis’s payout ratio is presently 34.42%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Piper Sandler raised their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. UBS Group lowered their price target on shares of Zoetis from $165.00 to $158.00 and set a “neutral” rating for the company in a research report on Monday, October 20th. Finally, Argus reiterated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research report on Tuesday, September 9th. Four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and an average price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.